Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acipimox on GLP-1 Secretion in Healthy Subjects
NCT02796950Completed
- Sponsor
- Aarhus University
- Start
- Jun 2016
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of acipimox in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Aarhus University. Primary endpoint: Glucagon-like peptide-1 levels at 9 months. Started Jun 2016; status: completed.
02
Drugs
acipimox
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02796950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02796950.